A randomized controlled study of Velcade (bortezomib) plus thalidomide plus dexamethasone compared to thalidomide plus dexamethasone for the treatment of myeloma patients progressing or relapsing after autologous transplantation.

Trial Profile

A randomized controlled study of Velcade (bortezomib) plus thalidomide plus dexamethasone compared to thalidomide plus dexamethasone for the treatment of myeloma patients progressing or relapsing after autologous transplantation.

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Apr 2014

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone; Thalidomide
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms MMVAR
  • Most Recent Events

    • 17 Jul 2012 Status changed from active, no longer recruiting to completed, based on final results published in J Clin Oncol.
    • 14 May 2012 Final results published in the Journal of Clinical Oncology.
    • 15 Sep 2010 Planned end date changed from 1 Dec 2009 to 1 Dec 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top